A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Atopic Dermatitis

Summary

The study is a Phase II, single center, randomized, open-label, placebo-controlled study in male and female subjects, aged ≥ 20 years with mild to moderate atopic dermatitis. All subjects will receive BID topical applications of PAC-14028 cream or vehicle or Elidel cream for up to 4 weeks.

Timeline

Start

2013-06

Primary completion

2014-01

Completion

2015-08

Drugs

Indications